Boehringer Ingelheim India Private Ltd.

 Mumbai 400 051 ∙ India Boehringer Ingelheim India

Private Ltd.

SPONSORSHIP AGREEMENT_ NON HCO

Cardicon-2009
Date: 13-11-2019
(hereinafter “Agreement”)
Contract No.: BI/DB/19-711
Between

Cardicon-2009
R K Singh Lane, Sumer Sagar Phone: +91-22-26456477 (B)

Gorakhpur -273001 India Fax: +91-22-26456163

PAN No.: AAAAC6239N Mailing Address &

GST-NA Registered Office:
1102, 11th Floor
Hallmark Business Plaza
Gurunanak Hospital Road
- hereinafter: “Grantee” – Near Gurunanak Hospital
Bandra East
and Mumbai – 400 051
INDIA
www.boehringer-ingelheim.in
BOEHRINGER INGELHEIM INDIA PVT. LTD.,
11th floor, Hallmark, Guru Nanak Hospital Road, CIN:U24230MH2003PTC143499
Bandra East, Mumbai – 400051,
CIN: U24230MH2003PTC143499

- hereinafter: “BI” –

- each party also referred to as a “Party” and both parties

collectively as the “Parties”-

Preamble Board of Directors

Boehringer Ingelheim India Pvt. Ltd is in the pharmaceutical Sharad Tyagi
company and is engaged in the activities necessary for marketing its Sandip Agrawal
Delvin Jacob Mathews
pharmaceutical products in India, and wishes to financially support Deutsche Bank AG, Mumbai
an event organised by the Grantee as further set forth in this Account No. 0537019
Agreement and the Grantee will announce BI as financial Swift: DEUTINBBXXX
contributor and grant sponsorship rights and benefits to BI.

BI and the Grantee agree as follows:

Page 2
ABCD
1. Obligations of the Grantee

1.1.The Grantee shall organize the event “Diabetes Symposium” which

will take place at Moradabad on 29th Nov 2019. The Grantee shall
ensure that the Event will take place and proceed as planned and
shall, subject to the policies of the Grantee, promote media
coverage of the Event.

1.2. The agenda of the Event is attached to this Agreement as Schedule

1.

1.3. As far as possible the Grantee announces BI´s role as a financial

contributor of the Event. In this respect, BI submits a graphical
element of the corporate symbol of BI to the Grantee and grants the
Grantee a non-exclusive right to use this symbol during the term of
this Agreement.

1.4. The Grantee appoints BI as a financial contributor of the Event and

grants BI the sponsorship rights and benefits as listed in Schedule 1.

2. Obligations of BI

2.1. BI agrees to be a financial contributor to the Event / Program and

shall pay a total amount of INR 2,55,000 (“Sponsorship Sum”) in
favour of the Grantee. Applicable tax shall be added to such
Sponsorship Sum, if applicable.

2.2. The Sponsorship Sum shall become due as follows:

(i) INR 2,55,000 as of 29th Nov 2019

2.3. BI undertakes to make all payments due hereunder within thirty

(30) days after receipt of an invoice from the Grantee to a bank
account designated by Grantee. Invoices shall be made as specified
in Schedule 2 and detailing Applicable tax separately. Schedule 2
shall be modified in the event of a change in the applicable legal
requirements.

2.4. BI hereby nominates Anshita Gupta phone no.9582743390 as the

contact person for all questions in connection with the Agreement by
Grantee to BI. BI is entitled to replace the contact person if needed.
Page 3
ABCD
3. Principles of the Agreement

3.1. BI and the Grantee agree and confirm that this Agreement has not
been concluded in order to influence current or future sales
transactions. The sponsorship does not commit the Grantee or its
employees to accept or prefer services or products from BI. BI does
not expect any preference for its products (Principle of Separation).

3.2. The Grantee shall observe all laws and industry regulations on the
cooperation of the pharmaceutical industry with medical
professionals, such as the applicable local Indian laws & implement
their current versions, to the extent such regulations and codes are
applicable to the Grantee’s organization and conduct of the Event /
performance of the Program.

3.3. Grantee represents and warrants that it, its owners, directors,
officers, employees, sub-contractors and agents will act in full
compliance with any applicable ABAC laws and regulations,
industry and professional codes of practice and will not offer,
promise, pay or arrange for payment or giving of a bribe or any
benefit, advantage or anything of value to any public official,
individual, entity or any other third party in exchange for an
improper advantage in any form either directly or indirectly.

3.4. Grantee shall strictly adhere to the applicable local laws. Grantee
further agrees that it will not provide either by itself or through its
authorized representative, any material consisting of either BI
company branding or BI product branding during the conduct of the
Event(s)/Program(s) or otherwise unless approved by BI in writing.
BI shall not be responsible for any act or omission of Grantee beyond
the context of this Agreement or in case of violation of this clause by
the Grantee.

3.5. The Grantee undertakes to use the Sponsorship Sum solely and
exclusively for the scientific and pharmaceutical program parts of the
Event / Program but not for the individual support of single
participants or employees of the Grantee, for entertainment, leisure,
or social events or for accompanying persons (i.e. family members)
etc. The Sponsorship Sum may be used for the following purposes:

1. Furthermore, the Grantee undertakes not to use the

participation fees for entertainment programs.

2. Grantee shall make all expenses according to

economic and efficient principles. Expenses shall not
exceed socially acceptable limitations.
Page 4
ABCD

3.6. Grantee shall make all expenses according to economic and

efficient principles. Expenses shall not exceed socially acceptable
limitations.

3.7. BI shall have the right to let independent auditors examine the
Grantee’s books and records for the purposes of ascertaining that the
Sponsorship Sum has been spent in accordance with the terms of this
Agreement.

4. Confidentiality

4.1. The Parties shall inform each other on any circumstances that may
be essential for the conduct of the Event / performance of the
Program.

4.2. The Parties undertake to keep confidential the content of this

Agreement. Neither Party shall be entitled to disclose any contractual
detail to any third party, unless it has obtained the written agreement
of the other Party or is obliged to do so under any applicable Indian
law. The confidentiality obligation shall survive the termination of
this Agreement.

5. Spend Report – Disclosure

5.1. Any data required for the cooperation with its contractual partners
is processed by BI in accordance with applicable data protection
laws. For accuracy check BI evaluates all data from healthcare
professionals and healthcare organisations with a database of an
external service provider. In case that personal data is forwarded to
third parties this is covered by a data processing agreement where the
third party acts on behalf of BI. In addition to this accuracy check BI
uses the personal data of its contractual partners exclusively for fair
market value check as well as for internal evaluation. For these
purposes the data may be forwarded within the BI group of
companies.

5.2. Pursuant to the applicable local laws of India, BI is obliged to

disclose any payments and transfer of value to healthcare
professionals (HCP) and healthcare organisations (HCO). The
obligation to disclosure includes information such as full name, city,
country, and address of principal practice, and amount and currency
of payment(s) and/or other transfer(s) of value. If applicable data
protection law explicitly prescribes a consent of the healthcare
Page 5
ABCD
professional or healthcare organisation, BI will provide detailed data
protection information and a declaration of consent template and
obtain such consent for disclosure in due time prior to the planned
disclosure.

6. Term and Termination

6.1. This Agreement shall become effective as of 29/11/2019 and shall

terminate on 28/12/2019.

6.2. Each Party shall have the right to terminate this Agreement for
cause. BI in particular has the right to such termination for cause if
the Grantee fails to conduct the Event / perform the Program as
agreed or does not fulfil its obligations under this Agreement. In this
case the Grantee shall reimburse the full Sponsorship Sum without
deduction

7. Concluding Provisions

7.1. This Agreement sets forth the entire agreement between the Parties
and supersedes all previous agreements, written or oral regarding the
subject matter hereof. Amendments of this Agreement may only be
made by mutual agreement and must be in written form.

7.2. The invalidity of any provision of this Agreement or a contractual

gap herein shall not affect the validity of any other provision hereof.
The Parties undertake to replace the invalid provision or close the
contractual gap with another provision which legally reflects the
originally intended commercial objectives of the Parties as closely as
possible.

7.3. This Agreement shall be governed exclusively by the laws of India.

In the event of any controversy or claim arising out of or relating to
any provision of this Agreement, the Parties shall first try to settle
those conflicts amicably between themselves. All disputes arising in
connection with this Agreement which cannot be settled amicably
shall be settled by the locally competent court for Mumbai, India.
Page 6
ABCD
BOEHRINGER INGELHEIM INDIA CARDICON-2009
PVT LTD

_______________________ ________________________
Mr. Ripan Puri Dr. Sudhir Kumar

_______________________
Dr. Shraddha Bhure

– authorised signatories –

Enclosures:
Schedule 1 – Sponsorship Benefits and Rights and Agenda of the Event
Schedule 2 – Acknowledgement Receipt
Page 7
ABCD

Schedule 1

Sponsorship Benefits and Rights

Satellite Symposium

 BI gains the right to organize for product display in the form

of standee, banner & 3 topics to discuss of 02:05 Hrs during
the meeting on 29th Nov 2019 at the main venue.
Page 8
ABCD

Agenda of the Event / Description of the Program

Page 9
ABCD

Schedule 2

Cardicon-2009
R K Singh Lane, Sumer Sagar
Gorakhpur -273001 India
PAN No.: AAAAC6239N

Boehringer Ingelheim India Pvt. Ltd.

1102, 11th floor, Hallmark,
Guru Nanak Hospital Road,
Bandra East,
Mumbai-400051
Maharashtra
India

- Date of invoice :- 29th Nov 2019.

- Amount due and currency :- 2,55,000/-
- Boehringer Ingelheim Contract No : -BI/DB/19-711